No additional consent elements are needed — the patient already consented to antipsychotic treatment.

The PMHNP should discuss the specific properties of long-acting formulations, including that the medication cannot be "stopped" once injected and will remain active for the duration of the injection cycle, potential injection site reactions, the implications for managing side effects, and the commitment to a specific dosing schedule.

Only the injection site risks need to be discussed — other risks are the same as oral formulations.

Written consent is required for injections but not for oral medications.